Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
(a) Aquestive Therapeutics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting") on June 11, 2025.
(b) The final voting on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.
(1) The following director nominees were elected to serve as Class I members of the Board of Directors, to serve for a three-year term until the Company's 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominee
|
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
Daniel Barber
|
36,060,882
|
-
|
3,546,668
|
29,848,112
|
Timothy E. Morris
|
35,562,599
|
-
|
4,044,951
|
|
(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.
|
|
|
|
|
|
|
|
|
|
|
|
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
32,454,278
|
6,694,084
|
459,188
|
29,848,112
|
(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 was ratified.
|
|
|
|
|
|
|
|
|
Votes For
|
Votes Against
|
Votes Abstaining
|
66,530,646
|
1,166,766
|
1,758,250
|